Pfizer, BioNTech not sure about vaccine effectiveness in new COVID version “Omicron”

The companies also promised to develop a new variant of the vaccine against it in about 100 days, Sputnik reports.

This followed the announcement by the World Health Organization (WHO) that it had identified a new strain of COVID-19, strain B.1.1.529, which was originally found in South Africa. The WHO named the variant with the Greek letter “Omicron”.

“If a mandatory variant of the vaccine emerges, Pfizer and BioNTech expect to be able to develop and manufacture a customized vaccine against this variant in about 100 days, subject to regulatory approval,” they added in a statement.

As Sputnik reports, Pfizer and BioNTech said they expect more information about Omicron over the next two weeks, noting that the variation is significantly different from what was previously observed.

The pharmaceutical companies stressed that they started working to make their vaccine adaptable to new possible variants months ago, adding that their vaccine is currently able to adapt in six weeks and deliver initial batches in 100 days, the statement said.

In a similar development, amid the spread of the Omicron variant, the World Trade Organization (WTO) postponed the 12th Ministerial Conference in Geneva on Saturday (MC12).

As a precautionary measure to prevent the spread of the new variant, India added to the list on Friday a number of countries from which passengers should take additional measures upon arrival in India, including post-arrival infection testing.

The United States as well as the European Union and other major destinations have also moved to block flights from several African countries, CNN reports.

Source: ANI

# COVID-19

Source: The Nordic Page





Related Posts